Radio and PodcastRadio and PodcastLive Radio & Podcasts
March 3, 2026: Hypertrophic Cardiomyopathy in Focus—MAPLE-HCM Trial, Myosin Inhibitors & What Improvement Really Means JACC This Week artwork
Science & Medicine

March 3, 2026: Hypertrophic Cardiomyopathy in Focus—MAPLE-HCM Trial, Myosin Inhibitors & What Improvement Really Means JACC This Week

JACC's Audio Podcasts by American College of Cardiology

Mar 3, 202618:10Science & Medicine

In this episode of JACC This Week, Dr. Carolyn Lam and Dr. Harlan Krumholz spotlight a mini-focus issue on hypertrophic cardiomyopathy (HCM), a field undergoing rapid transformation. The discussion centers on the MAPLE-H...

About This Episode

March 3, 2026: Hypertrophic Cardiomyopathy in Focus—MAPLE-HCM Trial, Myosin Inhibitors & What Improvement Really Means JACC This Week is an episode from JACC's Audio Podcasts by American College of Cardiology. In this episode of JACC This W...

Podcast

This episode belongs to JACC's Audio Podcasts.

Listen Online

Use the player on this page to stream the episode online.

Episode Details

Published Mar 3, 2026, 18:10 long, audio available.

Questions About This Episode

What is March 3, 2026: Hypertrophic Cardiomyopathy in Focus—MAPLE-HCM Trial, Myosin Inhibitors & What Improvement Really Means JACC This Week about?

In this episode of JACC This Week, Dr. Carolyn Lam and Dr. Harlan Krumholz spotlight a mini-focus issue on hypertrophic cardiomyopathy (HCM), a field undergoing rapid transformation. The discussion centers on the MAPLE-HCM trial comparing aficamten and metoprolol in symptomatic obstructive HCM, highlighting multidomain response analysis and what it means to measure meaningful improvement. Beyond gradients and biomarkers, the conversation explores a critical question: when physiologic surrogates improve, how should we interpret patient-centered outcomes? Framed by the Editor's Page, "What Does Improvement Mean?", this episode examines the evolving role of myosin inhibitors, disease modification, and the tension between surrogate markers and real-world clinical benefit. Additional highlights include disaggregation of Asian ethnicities in heart failure quality-of-care research and emerging evidence on AI-driven ECG models to predict incident heart failure—underscoring JACC's commitment to precision, equity, and innovation. This issue reflects a broader shift across cardiology: transforming once-static diseases into treatable chronic conditions guided by rigorous evidence.

Where can I listen to March 3, 2026: Hypertrophic Cardiomyopathy in Focus—MAPLE-HCM Trial, Myosin Inhibitors & What Improvement Really Means JACC This Week?

You can listen to March 3, 2026: Hypertrophic Cardiomyopathy in Focus—MAPLE-HCM Trial, Myosin Inhibitors & What Improvement Really Means JACC This Week online on Radio and Podcast. Open the player on this page to stream the available audio.

Which podcast is March 3, 2026: Hypertrophic Cardiomyopathy in Focus—MAPLE-HCM Trial, Myosin Inhibitors & What Improvement Really Means JACC This Week from?

March 3, 2026: Hypertrophic Cardiomyopathy in Focus—MAPLE-HCM Trial, Myosin Inhibitors & What Improvement Really Means JACC This Week is an episode from JACC's Audio Podcasts by American College of Cardiology.

How long is this episode?

This episode is 18:10 long.

When was this episode published?

This episode was published on Mar 3, 2026.

Can I save March 3, 2026: Hypertrophic Cardiomyopathy in Focus—MAPLE-HCM Trial, Myosin Inhibitors & What Improvement Really Means JACC This Week for later?

Yes. Use the heart button on the episode page to add it to your favorite episodes list.

Are there related episodes from JACC's Audio Podcasts?

Yes. This page shows related episodes from JACC's Audio Podcasts when more episodes are available from the podcast feed.

Quick Answers About This Episode

Where can I listen to March 3, 2026: Hypertrophic Cardiomyopathy in Focus—MAPLE-HCM Trial, Myosin Inhibitors & What Improvement Really Means JACC This Week?

You can listen to March 3, 2026: Hypertrophic Cardiomyopathy in Focus—MAPLE-HCM Trial, Myosin Inhibitors & What Improvement Really Means JACC This Week on this page when the episode audio is available from the podcast feed.

Which podcast is this episode from?

March 3, 2026: Hypertrophic Cardiomyopathy in Focus—MAPLE-HCM Trial, Myosin Inhibitors & What Improvement Really Means JACC This Week is from JACC's Audio Podcasts by American College of Cardiology.

What are the episode details?

Published Mar 3, 2026 and 18:10 long